Zerenia Clinic UK


14 October 2022 “Flower Power”: Controlled Inhalation of THC-Predominant Cannabis Flos Improves Health-Related Quality of Life and Symptoms of Chronic Pain and Anxiety in Eligible UK Patients Abstract In November 2018, the UK’s Home Office established a legal route for eligible patients to be prescribed cannabis-based products for medicinal use in humans (CBPMs) as unlicensed

April 2022 Khiron publishes clinical study on the effectiveness of its products at controlling chronic pain Data substantiates company’s position as a global leader in health care solutions. Key findings in the study include: 9 out of 10 patients reported improvement of their chronic pain. 7 out of 10 reported an improvement larger than 50%

The CBD-ilemma

March 2022 The CBD-ilemma The approval of epidyolex for the treatment of refractory pediatric epilepsy is providing an increasing body of evidence on the therapeutic potential of cannabidiol (CBD), which had already showed promise to address other clinical conditions such as anxiety, psychotic symptoms, or substance use disorders. Owing to this therapeutical promise and fueled

February 2022 Canex: The new medical cannabis clinic that wants to change the industry in the UK In partnership with Project Twenty21, a brand new clinics has just opened in the UK to fight inaccessibility and unaffordability of medical cannabis. Zerenia Clinics will go and try to change the industry and offer more patients the

February 2022 First Khiron specialist medical cannabis clinic opens in Europe Khiron Life Sciences Corp. is one of the world’s leading medical cannabis companies. Not only in Latin American countries such as Colombia, Peru, Brazil and now soon Mexico, Khiron has long been strongly represented in the market for medical cannabis, but also in Europe,